BSPGHAN 2021 Virtual Annual Meeting

27- 29 April 2021

TWO YEAR FOLLOW UP OF CHILDREN WITH INFLAMMATORY BOWEL DISEASE (IBD) TREATED WITH VEDOLIZUMAB AND USTEKINUMAB

Subscribe
Notify of
3 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
Rajiv Mohan
Rajiv Mohan
20 days ago
  1. Was there any defined age to start the monoclonal antibodies?
  2. Is 50% of children were primary non responder/secondary loss of response to Vedo/Ustek?
Roxana Mardare
Roxana Mardare
19 days ago
Reply to  Rajiv Mohan

Dear Rajiv,

Thank you for your questions. The main condition for starting Vedolizumab or Ustekinumab was failure of anti-TNF treatment, so there was no age limit. Our youngest patients were 4 years old.
10/27 children failed Vedolizumab or Ustekinumab. Out of these 10 patients, 5 patients were primary nonresponders, while the other 5 had secondary loss of response.
Please let me know if you have more questions. I would be more than happy to respond.

Rajiv Mohan
Rajiv Mohan
18 days ago
Reply to  Roxana Mardare

Thanks Roxana